Cilofexor, a FXR agonist, in combination with firsocostat, an acetyl-CoA carboxylase (ACC) inhibitor in the AMPK pathway, and/or semaglutide has been assessed in MASH patients (n = 109) for 24 weeks in a Phase 2a trial. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.